NCT01472627View on ClinicalTrials.gov

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Blood draws

Blood draws

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER